← Cintas overview

Cintas vs Leidos: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Cintas Corporation (CTAS)

Q3 2026
▲1▼1

Record Q1, dividend hike, but UniFirst deal faces FTC delay

  • Record Q1 results and raised guidance Cintas reported record fiscal Q1 revenue up about 11% to $3.01 billion and adjusted earnings per share up 15.8% to $1.39, then raised its full-year outlook and lifted its dividend 15.6%. Bank of America upgraded the stock.

    Strong earnings and a dividend increase are direct positive drivers of the stock.

  • FTC scrutiny delays UniFirst acquisition The $5.5 billion UniFirst acquisition faced FTC scrutiny, and the odds of the deal closing fell to roughly 70% from 85%, threatening expected growth and cost savings. Closing is barred before December 11 absent earlier clearance.

    Regulatory risk to a major acquisition is a key negative force on the stock.

  • Compliance certification lowers breakup risk Cintas and UniFirst later certified substantial compliance with the FTC's second request, which lowers the risk that the deal falls apart. However, the deal still cannot close before December 11 without earlier clearance.

    This reduces uncertainty but does not remove the regulatory hurdle, so it is mixed.

  • President and CEO roles split Cintas split its President and CEO roles, a move aimed at improving efficiency. The operational payoff is uncertain, so the market impact is mixed.

    A leadership change with unclear near-term effect is a mixed driver.

August 2026
▲1▼1

Record Q1, dividend hike, but UniFirst deal faces FTC delay

  • Record Q1 results and raised guidance Cintas reported record fiscal Q1 revenue up about 11% to $3.01 billion and adjusted earnings per share up 15.8% to $1.39, then raised its full-year outlook and lifted its dividend 15.6%. Bank of America upgraded the stock.

    Strong earnings and a dividend increase are direct positive drivers of the stock.

  • FTC scrutiny delays UniFirst acquisition The $5.5 billion UniFirst acquisition faced FTC scrutiny, and the odds of the deal closing fell to roughly 70% from 85%, threatening expected growth and cost savings. Closing is barred before December 11 absent earlier clearance.

    Regulatory risk to a major acquisition is a key negative force on the stock.

  • Compliance certification lowers breakup risk Cintas and UniFirst later certified substantial compliance with the FTC's second request, which lowers the risk that the deal falls apart. However, the deal still cannot close before December 11 without earlier clearance.

    This reduces uncertainty but does not remove the regulatory hurdle, so it is mixed.

  • President and CEO roles split Cintas split its President and CEO roles, a move aimed at improving efficiency. The operational payoff is uncertain, so the market impact is mixed.

    A leadership change with unclear near-term effect is a mixed driver.

Latest
▲3

Cintas beats, raises guidance, and clears a key FTC hurdle

  • Record quarter and raised outlook Cintas reported fiscal first-quarter revenue up 11% to $3.01 billion and adjusted EPS of $1.39, then raised its fiscal 2027 revenue and EPS guidance. A growing, more profitable core business supports a higher stock price.

    The latest earnings beat and guidance raise are the main new fundamental driver of CTAS shares.

  • UniFirst deal clears FTC compliance step Cintas and UniFirst certified they substantially complied with the FTC's second request and agreed not to close before Dec. 11 unless cleared sooner. This lowers the risk the $5.5 billion deal falls apart, supporting the stock.

    Regulatory progress on the UniFirst acquisition is a major new event affecting CTAS's growth outlook.

  • Dividend raised 15.6% Cintas lifted its quarterly dividend 15.6% to $0.52 per share, payable September 15. A bigger payout signals confidence in cash flow and rewards shareholders, which tends to support the stock.

    The dividend increase is a concrete new capital-return action for shareholders.

  • Leadership split puts focus on operations and capital Cintas separated the President and CEO roles, naming Jim Rozakis President and COO while Todd Schneider stays CEO. The change aims to sharpen efficiency and capital allocation, but the operational payoff is uncertain.

    The leadership change is a new governance event that could affect how Cintas is run and valued.

▲3▼1

Cintas beats and raises guidance, but UniFirst deal faces FTC hurdle

  • Record Q1 results and raised fiscal 2027 outlook Cintas reported record first-quarter revenue of $3.01 billion, up 10.9%, and adjusted EPS of $1.39, up 15.8%. It raised full-year revenue and EPS guidance and lifted its dividend 15.6%. This shows the core business is strong and growing, which supports a higher stock price.

    This is the most recent and concrete evidence of the company's strong operating performance, directly driving the stock up.

  • FTC scrutiny lowers odds of UniFirst acquisition Bernstein said the market-implied chance of the UniFirst deal closing fell to about 70% from 85% due to FTC civil investigative demands and a critical industry report. If the deal falls through, Cintas loses expected growth and cost savings, which pressures the stock.

    This is a new regulatory development that creates uncertainty and weighs on the stock price.

  • Strong Q4 results and initial fiscal 2027 guidance In July, Cintas reported Q4 revenue up 8.9% to $2.91 billion and adjusted EPS of $1.29, beating estimates. It guided fiscal 2027 revenue to $12.10–$12.25 billion and EPS to $5.36–$5.50, showing confidence in continued growth.

    This was the first signal of the company's strong momentum and set the stage for the subsequent stock gains.

  • Bank of America upgrade and analyst optimism Bank of America upgraded Cintas to buy in mid-July, helping shares gain 6.5% that day. Analyst upgrades can boost investor confidence and attract buyers, pushing the stock higher.

    This is a new analyst action that contributed to the stock's rise during the period.

Leidos Holdings Inc (LDOS)

Q3 2026
▲3▼1

Leidos expands AI and defense footprint, but profit falls and analyst downgrades

  • AI and defense partnerships Leidos formed a mainframe modernization partnership with Mechanical Orchard, a UK defence logistics alliance with DHL, and a CoreWeave partnership for classified AI cloud services, expanding its technology and defense footprint.

    These new partnerships show Leidos broadening its AI and defense capabilities, a key growth driver.

  • Major contract wins Leidos won missile-defense sensor work for 18 satellites, a $301M Army cyber award, an $875M Navy network deal, and a $127M Army ARTEMIS extension, adding significant new revenue opportunities.

    These large contract awards directly support future revenue growth and investor confidence.

  • Cybersecurity and AI product launches Leidos launched AI cybersecurity platform Parcata and demonstrated successful cyber detection at Valiant Shield, showcasing innovation in high-demand security areas.

    New product launches and successful demos highlight Leidos' competitive edge in cybersecurity and AI.

  • Profit decline and analyst downgrade Q2 profit fell to $354M from $391M despite 7.2% revenue growth, and J.P. Morgan downgraded the stock to Neutral with a $142 target, citing weak healthcare margins and lower earnings expectations.

    This negative news weighed on sentiment and the stock price, providing a counterweight to positive developments.

August 2026
▲2▼2

Leidos wins major defense contracts but profit falls and analyst downgrades

  • Major defense contract wins Leidos won several large defense contracts: missile-defense sensor work for 18 satellites, a $301M Army cyber contract, an $875M Navy network award, and a $127M Army ARTEMIS extension. These wins support future revenue growth.

    These new contracts are a key positive driver for the stock, showing strong demand for Leidos' defense services.

  • AI cybersecurity tool launch Leidos launched an AI cybersecurity tool for federal agencies, expanding its product offerings in the growing AI security market. This could open new revenue streams and strengthen its competitive position.

    This new product launch is a positive development that could drive future growth and is new information for this period.

  • Q2 profit decline despite revenue growth Leidos reported Q2 profit of $354M, down from $391M a year earlier, even though revenue grew 7.2%. This profit drop raises concerns about the company's ability to turn revenue growth into earnings.

    The decline in profit is a negative factor that weighs on investor sentiment and the stock price.

  • J.P. Morgan downgrade on margin weakness J.P. Morgan downgraded Leidos to Neutral with a $142 price target, citing weak healthcare margins and lower earnings expectations. This analyst caution adds pressure on the stock.

    The downgrade reflects concerns about profitability and can negatively impact the stock price.

Latest
▲2▼1

Leidos wins new contracts but faces healthcare margin downgrade

  • New Army ARTEMIS contract adds revenue visibility Leidos won a $127 million Army contract to extend ARTEMIS airborne intelligence operations through 2027. This concrete order supports future revenue and shows continued demand for Leidos's defense services, which helps the stock.

    This is a new contract award that directly boosts Leidos's backlog and revenue outlook.

  • New AI cyber tool for federal agencies Leidos launched UpHold Effect Agentic SOC Automation, an AI tool that helps federal cyber teams handle alerts. This new product could open a new growth area in cybersecurity for government, a plus for future revenue.

    This is a new product launch that could drive future revenue growth in a high-demand area.

  • Security screening joint venture completed Leidos completed the combination of its security screening businesses with Analogic, forming a new private company. Leidos keeps a minority stake and sharpens focus on its growth strategy, but the net financial impact is unclear.

    This is a major corporate event that changes Leidos's business mix and could affect future earnings.

  • J.P. Morgan downgrade on healthcare weakness J.P. Morgan downgraded Leidos to Neutral and cut its price target to $142, citing falling earnings expectations and weak healthcare margins. This negative analyst view can pressure the stock as investors adjust expectations.

    This is a new analyst downgrade that directly impacts investor sentiment and the stock's perceived value.

▲3▼1

Leidos racks up defense and Navy contract wins as profit slips

  • Missile-defense sensor work expands Leidos was picked to supply infrared sensors for 18 missile-tracking satellites, building on earlier payloads already in orbit. More satellite payload work means more revenue from a fast-growing defense area, which supports the stock.

    New contract win that adds demand and shows Leidos' role in missile defense.

  • AI cloud partnership for classified work Leidos and CoreWeave teamed up to build secure AI cloud services for U.S. intelligence and defense agencies, handling classified workloads. This opens a new growth area in AI for government, a plus for future revenue.

    New partnership that points to a new source of demand.

  • Q2 profit falls despite higher sales Second-quarter profit dropped to $354 million from $391 million a year earlier, even as revenue rose 7.2% to $4.56 billion. Lower profit weighs on the stock, though the company still guided to full-year revenue of $18.2-18.4 billion.

    New earnings result showing a real counterweight to the contract wins.

  • Army cyber and Navy network awards add backlog Leidos won a $301 million Army cyber-defense contract and an $875 million Navy network option year, keeping over 650,000 personnel connected. These awards extend key relationships and add revenue visibility, supporting the stock.

    New contract wins that directly add backlog and demand.

July 2026
▲5

Leidos expands federal AI and defense logistics with new partnerships

  • Mainframe modernization partnership Leidos partnered with Mechanical Orchard to bring its Imogen platform to federal agencies, helping modernize aging mainframe systems. This expands Leidos' service offerings and could lead to new contracts, supporting revenue growth and a higher stock price.

    New partnership expands Leidos' federal IT modernization business, a potential growth driver.

  • UK defence logistics alliance with DHL Leidos and DHL formed an alliance to pursue the UK MoD's Future Defence Support Services contract. If won, this major logistics deal would add significant long-term revenue and strengthen Leidos' international defense footprint, pushing the stock up.

    New alliance targets a large UK defense contract, a clear potential catalyst for future revenue.

  • Tactical cyber detection demo Leidos successfully demonstrated its CRS cyber detection system during the Valiant Shield military exercise. This showcases a new capability for military cyber resilience, which could attract future defense contracts and enhance Leidos' reputation in cyber warfare.

    New technology demonstration validates Leidos' cyber offerings, potentially leading to new business.

  • AI cybersecurity platform Parcata launched Leidos launched Parcata, an AI-driven platform that autonomously detects and patches cyber vulnerabilities in real time. This new product under the NorthStar 2030 strategy could open new revenue streams and position Leidos as a leader in AI cybersecurity.

    New product launch signals innovation and potential future revenue growth.

  • CoreWeave partnership for classified AI Leidos partnered with CoreWeave to deliver secure AI cloud services for U.S. intelligence and defense agencies. Leidos will lead mission integration and security, expanding its federal contracting opportunities in AI. The work is subject to future agreements and federal funding.

    New partnership opens access to high-growth classified AI work, a potential long-term revenue driver.

▲5

Leidos expands federal AI and defense logistics with new partnerships

  • Mainframe modernization partnership Leidos partnered with Mechanical Orchard to bring its Imogen platform to federal agencies, helping modernize aging mainframe systems. This expands Leidos' service offerings and could lead to new contracts, supporting revenue growth and a higher stock price.

    New partnership expands Leidos' federal IT modernization business, a potential growth driver.

  • UK defence logistics alliance with DHL Leidos and DHL formed an alliance to pursue the UK MoD's Future Defence Support Services contract. If won, this major logistics deal would add significant long-term revenue and strengthen Leidos' international defense footprint, pushing the stock up.

    New alliance targets a large UK defense contract, a clear potential catalyst for future revenue.

  • Tactical cyber detection demo Leidos successfully demonstrated its CRS cyber detection system during the Valiant Shield military exercise. This showcases a new capability for military cyber resilience, which could attract future defense contracts and enhance Leidos' reputation in cyber warfare.

    New technology demonstration validates Leidos' cyber offerings, potentially leading to new business.

  • AI cybersecurity platform Parcata launched Leidos launched Parcata, an AI-driven platform that autonomously detects and patches cyber vulnerabilities in real time. This new product under the NorthStar 2030 strategy could open new revenue streams and position Leidos as a leader in AI cybersecurity.

    New product launch signals innovation and potential future revenue growth.

  • CoreWeave partnership for classified AI Leidos partnered with CoreWeave to deliver secure AI cloud services for U.S. intelligence and defense agencies. Leidos will lead mission integration and security, expanding its federal contracting opportunities in AI. The work is subject to future agreements and federal funding.

    New partnership opens access to high-growth classified AI work, a potential long-term revenue driver.

Q2 2026
▲3▼1

Leidos loses key health contract, wins new defense and space work

  • Defense Health Agency plans to replace Leidos on MHS GENESIS The Defense Health Agency intends to replace Leidos as lead integrator on the MHS GENESIS military health records program. This threatens a major, multi-year revenue stream and has triggered analyst downgrades, weighing on the stock as investors reassess future margins and growth.

    This is the biggest new negative catalyst, directly hitting Leidos' revenue and profit outlook.

  • Leidos wins four State Department Evolve awards Leidos secured four awards under the State Department's $10 billion Evolve contract to modernize IT systems for diplomats worldwide. This adds a new, large, multi-year revenue opportunity, helping offset the loss of the health records work and supporting future growth.

    This is a fresh, sizable contract win that provides a positive counterweight to the negative health program news.

  • Leidos deploys Joint Management Tool with DISA and Space Command Leidos deployed a cloud-based Joint Management Tool with DISA and U.S. Space Command, giving combatant commands real-time satellite communications visibility. This showcases Leidos' software and defense modernization capabilities, reinforcing its relevance in high-growth military communications work.

    It demonstrates Leidos' strength in software-heavy defense work, a key positive driver for future demand.

  • Leidos advances DARPA regenerative fuel cell prototype Leidos demonstrated a working regenerative fuel cell under DARPA's ExCURSion program, cycling up to 1,000 times. This positions Leidos in cutting-edge energy storage technology for the military, potentially opening new long-term revenue streams and enhancing its reputation for innovation.

    It highlights Leidos' R&D strength and potential for future contracts in a novel technology area.

June 2026
▲3▼1

Leidos loses key health contract, wins new defense and space work

  • Defense Health Agency plans to replace Leidos on MHS GENESIS The Defense Health Agency intends to replace Leidos as lead integrator on the MHS GENESIS military health records program. This threatens a major, multi-year revenue stream and has triggered analyst downgrades, weighing on the stock as investors reassess future margins and growth.

    This is the biggest new negative catalyst, directly hitting Leidos' revenue and profit outlook.

  • Leidos wins four State Department Evolve awards Leidos secured four awards under the State Department's $10 billion Evolve contract to modernize IT systems for diplomats worldwide. This adds a new, large, multi-year revenue opportunity, helping offset the loss of the health records work and supporting future growth.

    This is a fresh, sizable contract win that provides a positive counterweight to the negative health program news.

  • Leidos deploys Joint Management Tool with DISA and Space Command Leidos deployed a cloud-based Joint Management Tool with DISA and U.S. Space Command, giving combatant commands real-time satellite communications visibility. This showcases Leidos' software and defense modernization capabilities, reinforcing its relevance in high-growth military communications work.

    It demonstrates Leidos' strength in software-heavy defense work, a key positive driver for future demand.

  • Leidos advances DARPA regenerative fuel cell prototype Leidos demonstrated a working regenerative fuel cell under DARPA's ExCURSion program, cycling up to 1,000 times. This positions Leidos in cutting-edge energy storage technology for the military, potentially opening new long-term revenue streams and enhancing its reputation for innovation.

    It highlights Leidos' R&D strength and potential for future contracts in a novel technology area.

▲3▼1

Leidos loses key health contract, wins new defense and space work

  • Defense Health Agency plans to replace Leidos on MHS GENESIS The Defense Health Agency intends to replace Leidos as lead integrator on the MHS GENESIS military health records program. This threatens a major, multi-year revenue stream and has triggered analyst downgrades, weighing on the stock as investors reassess future margins and growth.

    This is the biggest new negative catalyst, directly hitting Leidos' revenue and profit outlook.

  • Leidos wins four State Department Evolve awards Leidos secured four awards under the State Department's $10 billion Evolve contract to modernize IT systems for diplomats worldwide. This adds a new, large, multi-year revenue opportunity, helping offset the loss of the health records work and supporting future growth.

    This is a fresh, sizable contract win that provides a positive counterweight to the negative health program news.

  • Leidos deploys Joint Management Tool with DISA and Space Command Leidos deployed a cloud-based Joint Management Tool with DISA and U.S. Space Command, giving combatant commands real-time satellite communications visibility. This showcases Leidos' software and defense modernization capabilities, reinforcing its relevance in high-growth military communications work.

    It demonstrates Leidos' strength in software-heavy defense work, a key positive driver for future demand.

  • Leidos advances DARPA regenerative fuel cell prototype Leidos demonstrated a working regenerative fuel cell under DARPA's ExCURSion program, cycling up to 1,000 times. This positions Leidos in cutting-edge energy storage technology for the military, potentially opening new long-term revenue streams and enhancing its reputation for innovation.

    It highlights Leidos' R&D strength and potential for future contracts in a novel technology area.